Pfizer sues for Lipitor protection till 2016

Pfizer is hitting back at would-be Lipitor copycat Ranbaxy. The drugs giant sued the generics maker for patent infringement over the blockbuster cholesterol med Lipitor and Caduet, a combo of Lipitor and blood-pressure med Norvasc. Already blocked from selling copycat versions of the drugs till 2010, Ranbaxy would be stymied till 2016 if Pfizer's legal maneuvering succeeds.

Lipitor, of course, is Pfizer's cash cow, with $12.7 billion in 2007 sales, more than a quarter of the company's revenues; Caduet brought in $568 million. The suits allege that generic Lipitor and Caduet would trample on two Lipitor process patents, which don't expire until 2016. Pfizer asked the court to ban Ranbaxy from making, selling, or importing generic Lipitor till then. A Canadian court recently ruled in Pfizer's favor, protecting Lipitor from Ranbaxy until 2010.

- read the article at MarketWatch
- see the story at India Infoline
- check out Pfizer's release on the Canadian ruling

ALSO: EMTs to Lipitor's rescue? A union representing emergency medical techs and paramedics recently mailed a letter to its doctors' network endorsing the cholesterol med. "When appropriate, we ask that you please consider an agent like Lipitor for our members with high cholesterol," an official of the International Association of EMTs and Paramedics wrote. "IAEP leadership stands behind Lipitor as the lipid-lowering agent of choice." Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.